A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States

Mavranezouli, Ifigeneia
December 2010
PharmacoEconomics;2010, Vol. 28 Issue 12, p1109
Academic Journal
Economic evaluation of health technologies in the form of cost-utility analysis is increasingly advocated. The most common outcome measure in this type of analysis is the QALY. In order to estimate QALYs, appropriate utility values are required. The objective of this review was to identify and critique utility values for schizophrenia-related health states. A critical appraisal was performed on utility values for schizophrenia identified in the systematic literature review that informed the economic analysis of the updated edition of the National Institute for Health and Clinical Excellence (NICE) clinical guideline on schizophrenia for England and Wales. Seven studies reporting utility values for schizophrenia were identified. The studies employed a variety of methods for generating utility values. None of the reported sets of utility values for schizophrenia were generated using the EQ-5D, which is a measure widely used in cost-utility analysis and preferred by NICE. Nevertheless, the EQ-5D may be less sensitive in capturing aspects of health-related quality of life in patients with schizophrenia. A condition-specific preference-based instrument may be more appropriate than a generic measure to inform cost-utility analyses of interventions for schizophrenia.


Related Articles

  • NICE result for Exogen and Watch BP Home A.  // PharmacoEconomics & Outcomes News;1/26/2013, Issue 670, p11 

    The article reports that a medical technology guidance supporting the Exogen ultrasound bone healing system and the WatchBP Home A device has been published by the National Institute for Health and Clinical Excellence (NICE) in Great Britain.

  • Proposed amendments to NICE's HTA methods criticised.  // PharmacoEconomics & Outcomes News;Oct2014, Vol. 713 Issue 1, p8 

    The article reports on commentaries published in the journal "PharmacoEconomics," which include one by Mike Paulden from University of Alberta, Edmonton, on NICE's previous amendments to its methods for health technology appraisal (HTA) and another by Suzanne R. Hill and Leslie G. Olson from...

  • New Challenges for NICE. Upton, Julian // Pharmaceutical Executive;Feb2010, Vol. 30 Issue 2, p26 

    The article presents the challenges faced by the National Institute for Health and Clinical Excellence (NICE) to address application of cost-effective health resource allocation in Great Britain. It mentions the criticism faced by NICE concerning the quality-adjusted life year (QALY) as metric...

  • Mapping for economic evaluation. Chuang, Ling-Hsiang; Whitehead, Sarah J. // British Medical Bulletin;Mar2012, Vol. 101 Issue 1, p1 

    Introduction/background Mapping provides a statistical algorithm that allows the estimation of utilities and consequently calculation of QALYs in clinical studies where preference-based measures are not implemented. Sources of data Reviews of the mapping literature were utilized. Areas of...

  • Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura: A NICE Single Technology Appraisal. Boyers, Dwayne; Xueli Jia; Jenkinson, David; Mowatt, Graham // PharmacoEconomics;2012, Vol. 30 Issue 6, p483 

    The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of eltrombopag (GlaxoSmithKline) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of patients with chronic immune or idiopathic thrombocytopenic purpura (ITP), as...

  • Should NICE'S threshold range for cost per QALY be raised? Towse, Adrian // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/31/2009, p268 

    The article argues that the National Institute for Health and Clinical Excellence should fund cost-effective treatments. Topics are the guidelines for quality adjusted life year (QALY), the willingness of taxpayers to support the treatment costs for end-of-life drugs, the opportunity costs that...

  • Rationing: it would be NICE to consider patients' views. Speight, Jane; Reaney, Matt // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/31/2009, p297 

    The article offers the author's personal view on rationing health care and the cost effectiveness criteria set out by the National Institute for Health and Clinical Excellence (NICE) in Great Britain. Topics include NICE's appraisals of quality adjusted life years or QALYs by a method called...

  • NICE recommendations submitted by Kennedy.  // PharmacoEconomics & Outcomes News;8/8/2009, Issue 584, p3 

    The article focuses on the recommendations submitted by Professor Sir Ian Kennedy to the British National Institute for Health and Clinical Excellence (NICE) for the inclusion of social benefits in the institute's appraisals structure. Kennedy believes that such benefits should not create an...

  • NICE to extend end-of-life drug funding.  // PharmacoEconomics & Outcomes News;4/1/2013, Issue 675, p9 

    The article reports on the implications of the decision made by the National Institute for Health and Care Excellence (NICE) to improve the Great Britain National Health Service (NHS), which may lead to significant quality-adjusted life year (QALY) losses and budgetary problems to the service.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics